CAnCeR GenOMICS & PROTeOMICS - …cgp.iiarjournals.org/content/10/6/277.full.pdf · Articles in CAnCeR GenOMICS & PROTeOMICS are regularly indexed in the ... Y. YAnG (Beijing; Hami,

CAnCeRGenOMICS &PROTeOMICSPublished by the International Institute of Anticancer ResearchISSn (print): 1109-6535; ISSn (online): 1790-6245

Volume 10, 2013

Index

Editorial BoardA. Seth editor-in-Chief

Laboratory of Molecular Pathology, Sunnybrook Research Institute, Sunnybrook Health Sciences Centreand University of Toronto, Toronto, Ontario, Canada

J.G. Delinasios Managing editor and executive PublisherInternational Institute of Anticancer Research, Athens, Greece

L.A. Aaltonen department of Medical Genetics, University of Helsinki, FinlandR. Abagyan The Scripps Research Institute, La Jolla, CA, USAF. Ahmed department of Radiation Oncology, east Carolina University School of Medicine, Greenville, nC, USAS. Antonarakis division of Medical Genetics, University of Geneva Medical School, SwitzerlandD.-T. Bau Terry Fox Cancer Research Lab, China Medical University Hospital, Taichung, TaiwanM.R. Chance Case Western Reserve University, Center for Proteomics and Bioinformatics, Cleveland, OH, USAA.M. Chinnaiyan department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USAB.F.C. Clark department of Molecular Biology, University of Aarhus, denmarkR. Clarke Vincent T. Lombardi Cancer Center, Georgetown University School of Medicine, Washington, dC, USAN. E. Davidson University of Pittsburgh, Cancer Institute, Pittsburgh, PA, USAI. Dunham european Bioinformatics Institute, Wellcome Trust Genome Campus, Cambridge, UKT. Efferth department of Pharmaceutical Biology Institute of Pharmacy and Biochemistry, University of Mainz, GermanyJ.A. Fernandes-Pol Metalloproteomics, LLC, Chesterfield, MO, USAC.V. Forst department of Clinical Sciences, UT Southwestern Medical Center, dallas, Tx, USAM. Fountoulakis F. Hoffman-La Roche Pharmaceutical Research, Basel, SwitzerlandD.S. Gerhard nIH / nCI, Office of Cancer Genomics, Bethesda, Md, USAT.R. Golub Pediatric Oncology, dana-Farber Cancer Institute, Cambridge, MA, USAJ. Gordon department of neuroscience, Center for neurovirology, Temple University School of Medicine, Philadelphia,

PA, USAJ.W. Gray OHSU Knight Cancer Institute, Biomedical engineering, Portland, OR, USAB.B. Haab Van Andel Research Institute, Grand Rapids, MI, USAC.-H. Heldin Ludwig Institute for Cancer Research, Uppsala, SwedenJ.D. Hoheisel deutsches Krebsforschungszentrum, Genome Research and Bioinformatics, Heidelberg, GermanyR.P. Huang RayBiotech, Inc., norcross, GA, USAT.H.M. Huang department of Molecular Medicine/Institute of Biotechnology, University of Texas Health Science Center at San

Antonio, San Antonio, Tx, USAS.C. Jhanwar departments of Pathology and Medicine, Memorial Sloan Kettering Cancer Center, new York, nY, USAV.C. Jordan department of Oncology, Lombardi Comprehensive Cancer Center, Washington, dC, USAJ. Ju Translational Research Laboratories, State University of new York, School of Medicine, Stony Brook, nY, USAA. Kallioniemi Laboratory of Cancer Genetics, Institute of Medical Technology, Tampere University Hospital, FinlandO.P. Kallioniemi Medical Biotechnology Group, VTT Technical Research Centre of Finland, Turku, FinlandK. Khalili College of Science and Technology, Center for neurovirology and Cancer Biology, Temple University,

Philadelphia, PA, USAD.G. Kieback department of Obstetrics and Gynecology, elblandklinikum, Riesa (dresden), GermanyS.D. Kottaridis department of Virology, Hellenic Anticancer Institute, Athens, GreeceB. Léyland-Jones edith Sanford Breast Cancer Research, Sanford Health, Sioux Falls, Sd, USAP. Lichter deutsches Krebsforschungszentrum, Heidelberg, GermanyA. Lindblom Karolinska Hospital, department of Molecular Medicine and Surgery, Stockholm, SwedenG. Lubec department of Pediatrics, University of Vienna, AustriaJ. Lyons-Weiler department of Pathology, Center for Oncology Informatics, University of Pittsburgh, PA, USAP.J. McCormick The Center for Functional Genomics, Gen*nY*Sis Center for excellence in Cancer Genomics, University of

Albany, SUnY, Rensselaer, nY, USAJ.D. Minna Hamon Center for Therapeutic Oncology, University of Texas, Southwestern Medical Center at dallas, Tx, USAF. Mitelman department of Clinical Genetics, University Hospital, Lund, SwedenP. Nelson Fred Hutchinson Cancer Research Center, Seattle, WA, USAC. Nicot deparment of Microbiology, Immunology and Molecular Genetics, University of Kansas Medical Center,

Kansas City, KS, USA

279

CANCER GENOMICS & PROTEOMICS 10: (2013)

L. O’Driscoll School of Pharmacy and Pharmaceutical Sciences, Trinity College, dublin, IrelandI. Pastan Laboratory of Molecular Biology, nCI, nIH, Bethesda, Md, USAC.D. Platsoucas College of Sciences, Old dominion University, norfolk, VA, USAJ. Quackenbush department of Biostatistics and Computational Biology, dana-Farber Cancer Institute, Boston, MA, USAJ.S. Rader department of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, WI, USAA. Raouf department of Immunology, Faculty of Medicine, University of Manitoba, Winnipeg, MB, CanadaG. Rasty department of Anatomic Pathology, University Health network, University of Toronto, Toronto, On, CanadaG. Rechavi Pediatric Hemato-Oncology department, Sheba Medical Center, Tel-Hashomer, Israel R.H. Reeves department of Physiology, Johns Hopkins University, School of Medicine, Baltimore, Md, USAK.L. Reichelt Institute of Pediatric Research, The national Hospital, University of Oslo, norwayT. Ried Center for Cancer Research, Genetics Branch, nCI, nIH, Bethesda, Md, USAG. Rimbach Institute for Human nutrition and Food Science, Christian-Albrechts-University, Kiel, GermanyK.D. Rodland Biological Sciences division, Pacific northwest national Laboratory, Richland, WA, USAY. Sakaki Toyohashi University of Technology, Toyohashi, JapanC. Sansom The School of Crystallography, Birbeck College, University of London, UKN.A. Saunders Centre for Immunology and Cancer Research, Princess Alexandra Hospital, University of Queensland, AustraliaB.W. Schäfer department of Oncology, University Children’s Hospital, Zurich, SwitzerlandJ. Schneider Universidad Rey Juan Carlos, Facultad de Ciencias de la Salud, Alcorcón (Madrid), SpainO.J. Semmes department of Microbiology and Molecular Cell Biology, eastern Virginia Medical School, norfolk, VA, USAG.V. Sherbet University of newcastle, Merz Court, department of electrical and electronic engineering,

newcastle-upon-Tyne, UKK.K. Singh University of Alabama at Birmingham, department of Genetics/Cancer Research, Birmingham, AL, USAS. Smith City of Hope Cancer Center, department of Cell and Tumor Biology, duarte, CA, USAJ.C. Strefford Cancer Science division, Southampton General Hospital, Southampton, UKJ.M. Trent Tgen, Phoenix, AZ, USAG. Tsangaris Foundation of Biomedical Research of the Academy of Athens, Central Unit of Genomics-Proteomics,

Athens, GreeceL.-C. Tsui University of Hong Kong, Hong KongG.F. Vande Woude Laboratory of Molecular Oncology, Van Andel Institute, Grand Rapids, MI, USAD.K. Watson department of Pathology & Laboratory Medicine, The James e. Clyburn Research Center, Medical

University of South Carolina, Charleston, SC, USAA.T. Yeung Fox Chase Cancer Center, Philadelphia, PA, USAH. Zhang department of epidemiology and Public Health, Yale University School of Medicine, new Haven, CT, USA

Articles in CAnCeR GenOMICS & PROTeOMICS are regularly indexed in the following bibliographic services:PUBMed, MedLIne, CAS (Chemical Abstracts Service); BIOLOGICAL ABSTRACTS; eMBASe and BIOBASe; Compendex,GeOBASe; eMBiology; FLUIdex; Scopus (elsevier Bibliographic databases); BIOSIS PReVIeWS; Science Citation Indexexpanded (Web fo Science); Google Scholar; LeedS MedICAL InFORMATIOn; CSA ILLUMInA (Cambridge ScientificAbstracts, including: Oncogenes & Growth Factors, Genetics, Medical & Pharmaceutical Biotechnology, Bioengineering); All-RussianInstitute of Scientific and Technical Information – VInITI Abstracts Journal; PubsHub; Sociedad Iberoamericana de InformaciónCientífíca (SIIC) data Bases.

Editorial Office:International Institute of Anticancer Research1st km Kapandritiou-Kalamou Road, P.O. Box 22, Kapandriti, Attiki, 19014, Greece.Tel: +30 22950 52945, Fax: +30 22950 53389e-mail: [email protected]. Web: www.iiar-anticancer.org; www.cgp.iiarjournals.org

Manuscripts and correspondence, should be addressed to: dr. John G. delinasios, Managing editor, editorial Office, Cancer Genomics &Proteomics, 1st km Kapandritiou-Kalamou Road, P.O. Box 22, Kapandriti, Attiki, 19014, Greece. Tel: +30 22950 52945, Fax: +30 2295053389, e-mail: [email protected]

Manuscripts from north America may be sent to the editor-in-Chief, Prof. A. Seth, CGP, Laboratory of Molecular Pathology,Sunnybrook Research Institute, 2075 Bayview Avenue, Room S112a, Toronto, On, Canada M4n 3M5. Fax: +1 416 480 5737, e-mail:[email protected]

280


Albert Hung, Hong Kong, China

Breast Cancer Hope Foundation, London, U.K.

Cancer Research Wales, Wales, U.K. China Medical University and Hospital, Taichung, Taiwan,

R.O.C. Consejería de Sanidad, Junta de Castilla y León,

Valladolid, Spain Croatian Science Foundation, Opatija, Republic of Croatia

department of Health and Human Services, nationalCancer Institute, national Institutes of Health, Bethesda,Md, U.S.A.

epigenomics AG, Berlin, Germany

Fundación Caja de Burgos, Burgos, SpainFundación Memoria de don Samuel Solórzano Barruso,

Salamanca, Spain

Global Center of excellence for education and Researchon Signal Transduction Medicine in the ComingGeneration , Ministry of education, Culture, Sports,Science, and Technology of Japan, Tokyo, Japan

Grupo excelencia de Castilla y León, Castile and León,Spain

Institute for Research in Biotechnology , GeM Tox Labs,Greenville, nC, U.S.A.

Institute of Immunology, University of Rostock, Rostock,Germany

Instituto de Salud Carlos III (ISCIII), Ministerio deCiencia e Innovación, Madrid, Spain

Liddy Shriver Sarcoma Initiative, Ossining, nY, U.S.A.Life Technologies, darmstadt, Germany

Mathworks, natick, MA, U.S.A. Ministerio de Sanidad y Consumo, Madrid, Spain Ministry of Agriculture, Forestry and Fisheries of Japan,

Tokyo, Japan Ministry of education, Culture, Sports, Science, and

Technology of Japan, Tokyo, Japan Ministry of Health and Welfare, Seoul, Republic of KoreaMinistry of Science and Higher education of Poland,

Warsaw, PolandMinistry of Science, education and Sport, Zagreb,

Republic of Croatia

national Cancer Institute, nIH, Bethesda, Md, U.S.A.national Institutes of Health, Bethesda, Md, U.S.A.national natural Science Foundation of China, Guangdong,

P.R. Chinanorth Carolina Office of Science and Technology, Raleigh,

nC, U.S.A.

Red Temática de Investigación Cooperativa en Cáncer(RTICC), Salamanca, Spain

Royal College of Surgeons england, London, U.K.

San Raffaele Foundation, Milan, Italy

Terry Fox Cancer Research Foundation, Chilliwack, BC,Canada

AcknowledgementsThe following Organisations supported many of the works published in CAnCeR GenOMICS & PROTeOMICS, Volume 10,2013.

281


Number 1Review: The Intriguing Options of Multispecific Antibody Formats for Treatment of Cancer. U.H. WeIdLe,G. TIeFenTHALeR, e.H. WeISS, G. GeORGeS, U. BRInKMAnn (Penzberg; Munich, Germany) ......

Review: Genomics and Proteomics Approaches for Biomarker discovery in Sporadic Colorectal Cancer withMetastasis. M. GOnZÁLeZ-GOnZÁLeZ, J. GARCIA GARCIA, J.A. ALCAZAR MOnTeRO, L.M.GOnZÁLeZ FeRnAndeZ, O. BenGOeCHeA, O. BLAnCO MUÑeZ, A. ORFAO, J.M. SAYAGUeS,M. FUenTeS (Salamanca, Spain) ...................................................................................................

Association of p21, p21 p27 and p21 p53 Status to Histological Subtypes and Prognosis in Low-stageepithelial Ovarian Cancer. I. SKIRnISdOTTIR, T. SeIdAL (Uppsala; Halmstad, Sweden) .....................

Identification by High-throughput In Silico Screening of Radio-protecting Compounds Targeting the dnA-binding domain of the Tumor Suppressor p53. T. eICHHORn, C. HILLeR, K. HIRSCHFeLdeR, M.FRAnK, R.L. KRAUTH-SIeGeL, R. MÜLLeR, R. MeRTenS, T. eFFeRTH (Mainz; Heidelberg;Saarbrücken; Aachen, Germany) .......................................................................................................

The differential expression of Vascular endothelial Growth Inhibitor Isoforms, VeGI251, VeGI174 andVeGI192 in Human Clear-cell Renal Cell Carcinoma. n. ZHAnG, P. WU, L. WU, d. SHAYIReMU, H.SHAn, L. Ye, W.G. JIAnG, K. GOnG, Y. YAnG (Beijing; Hami, Xinjiang, PR, China; Cardiff, UK) ...

Number 2Clinicopathological Correlation and Prognostic Significance of VeGF-A, VeGF-C, VeGFR-2 and VeGFR-3expression in Colorectal Cancer. S.F. MARTInS, e.A. GARCIA, M.A.M. LUZ, F. PARdAL, M. ROdRIGUeS, A.L. FILHO (Braga; Guimarães; Vila Real, Portugal; São Paulo, Brazil) ..................

Guanine nucleotide Binding Protein β 1: A novel Transduction Protein with a Possible Role in Human BreastCancer. U. WAZIR, W.G. JIAnG, A.K. SHARMA, K. MOKBeL (London; Cardiff, Wales, UK) ................

Significant Association of Caveolin-1 Single nucleotide Polymorphisms with Childhood Leukemia in Taiwan.C.-H. WAnG, Y.-L. LAI, W.-S. CHAnG, K.-H. WU, H.-Y. LAne, C.-F. CHIU, F.-J. TSAI, C.-C. LIn, d.-T. BAU (Taichung, Taiwan, ROC) ...................................................................................................

expression of NFkB1, GADD45A and JNK1 in Salivary Gland Carcinomas of different Histotypes. G. GŐBeL, I. SZAnYI, P. RÉVÉSZ, M. BAUeR, I. GeRLInGeR, Α. nÉMeTH, I. eMBeR, K. GOCZe,K. GOMBOS (Pecs, Hungary) .........................................................................................................

dihydropyrimidine dehydrogenase Gene (DPYD) Polymorphism among Caucasian and non-CaucasianPatients with 5-FU- and Capecitabine-related Toxicity Using Full Sequencing of DPYD. M.W. SAIF(Boston, MA, USA) .........................................................................................................................

Number 3diagnostic MicroRnA Markers to Screen for Sporadic Human Colon Cancer in Stool: I. Proof of Principle. F.e.AHMed, n.C. AHMed, P.W. VOS, C. BOnneRUP, J.n. ATKInS, M. CASeY, G.J. nUOVO, W.nAZIRI, J.e. WILeY, H. MOTA, R.R. ALLISOn (Greenville, NC; Goldsboro, NC, USA) .....................

1

19

27

35

47

55

69

75

81

89

93

Contents, Volume 10, 2013


*

*

283

*

*


Mutational Analysis of Gastrointestinal Stromal Tumors (GISTs): Procedural Approach for diagnostic Purposes.R. PALMIROTTA, M.L. de MARCHIS, G. LUdOVICI, B. LeOne, R. COVeLLO, S. COnTI, L.COSTAReLLI, d. deLLA-MORTe, P. FeRROnI, M. ROSeLLI, F. GUAdAGnI (Rome, Italy; Miami,FL, USA) ......................................................................................................................................

Proteomic Analysis of normal Murine Brain Parts. V.K. TARASLIA, A. KOUSKOUKIS, A.K.AnAGnOSTOPOULOS, d.J. STRAVOPOdIS, L.H. MARGARITIS, G.TH. TSAnGARIS (Athens,Greece) ..........................................................................................................................................

Number 4Review: The emerging Role of new Protein Scaffold-based Agents for Treatment of Cancer. U.H. WeIdLe, J.AUeR, U. BRInKMAnn, G. GeORGeS, G. TIeFenTHALeR (Penzberg, Germany) ...........................

Review: The Role of Thiamine in Cancer: Possible Genetic and Cellular Signaling Mechanisms. K.V. QUỐCLƯƠnG, L.T. HOÀnG nGUYỄn (Westminster, CA, USA) .................................................................

A Role for WISP2 in Colorectal Cancer Cell Invasion and Motility. K.A. FReWeR, A.J. SAndeRS, S.OWen, n.C. FReWeR, R. HARGeST, W.G. JIAnG (Cardiff, UK) ...................................................

Number 5Gene expression Profiling of Circulating natural Killer Cells in Head and neck Squamous Cell Carcinoma. A. BÖTTCHeR, J. OSTWALd, d. KOCZAn, R. KneCHT, B. KRAMP, S. dOMMeRICH (Hamburg;Rostock; Berlin, Germany) ...............................................................................................................

Genotoxic effect of Two Bleaching Agents on Oral Mucosa. e. KLARIC, M. PAR, I. PROFeTA, n. KOPJAR,R. ROZGAJ, V. KASUBA, d. ZeLJeZIC, Z. TARLe (Zagreb, Croatia) .............................................

SHOX2 dnA Methylation Is a Tumour Marker in Pleural effusions. P. ILSe, S. BIeSTeRFeLd, n.POMJAnSKI, C. FInK, M. SCHRAMM (Düsseldorf, Germany) ........................................................

The Influence of Selol on the expression of Oxidative Stress Genes in normal and Malignant Prostate Cells. I.KSIAZeK, K. SITARZ, M. ROSLOn, e. AnUSZeWSKA, P. SUCHOCKI, J.d. WILCZYnSKA (Warsaw,Poland) .........................................................................................................................................

Serum and Tissue Metabolomics of Head and neck Cancer. K. YOneZAWA, S. nISHIUMII, J. KITAMOTO-MATSUdA, T. FUJITA, K. MORIMOTO, d. YAMASHITA, M. SAITO, n. OTSUKI, Y. IRInO, M.SHInOHARA, M. YOSHIdA, K.-I. nIBU (Kobe, Japan) ...................................................................

Number 6Review: The Translational Potential for Target Validation and Therapy Using Intracellular Antibodies in Oncology.U.H. WeIdLe, d. MAISeL, U. BRInKMAnn, G. TIeFenTHALeR (Penzberg, Germany) ...................

Rho Kinase Proteins Regulate Global miRnA expression in endothelial Cells. J.M. STILeS, V. KURISeTTY,d.C. MITCHeLL, B.A. BRYAn (El Paso, TΧ, USA) ........................................................................

115

125

155

169

187

197

209

217

225

233

239

251

*

Brain-metastatic Triple-negative Breast Cancer Cells Regain Growth Ability by Altering Gene expression Patterns.Y.-K. CHOI, S.-M. WOO, S.-G. CHO, H.e. MOOn, Y.J. YUn, J.W. KIM, d.-Y. nOH, B.H. JAnG, Y.C.SHIn, J.-H. KIM, H.d. SHIn, S.H. PAeK, S.-G. KO (Seoul, Korea) .................................................

Index 2013 ............................................................................................................................................

Reviews in Volume 10, pages: 1, 19, 155, 169, 239.

265

277

284


*

Subject Index(Figures refer to page numbers)

Amino acid, metabolomics, serum, tissue, glycolytic pathway,head and neck cancer, 233

Angiogenesis, extension of plasma half-life, HeR signaling;multivalent, multispecific, pharmacokinetics, phage andribosome display, randomisation of loops and β sheets,review, 155

Angiogenesis, Rho kinase, ROCK, endothelial cell, tumorvasculature, shRnA, miRnA, microarrays, 251

Angiogenesis, VeGI, VeGI isoform, clear-cell renal cellcarcinoma, 47

Antibody formats, cytokine delivery, death receptors, HeRsignaling, recruitment of immune effector cells, inhibition ofangiogenesis, review, 1

Apoptosis, breast cancer, GnB1, tumour suppressor gene,PCR, autophagy, 69

Autoimmune disease-related antibodies, cancerimmunotherapy against intracellular targets, intracellularimmunization, inhibition of oncogenic pathways,mechanisms of antibody uptake, protein knock-down, targetvalidation, protein transduction domain, review, 239

Autophagy, breast cancer, apoptosis, GnB1, tumoursuppressor gene, PCR, 69

Bioinformatics, diagnosis, gene expression, histopathology,microarrays, QC, RnA, RT-qPCR, staging, statistics, coloncancer, miRnA, stool samples, 93

Biomarker, cytology, pleural effusion, dnA methylation,SHOx2, malignant tumour, lung cancer, breast cancer,quantitative methylation-specific PCR, 217

Brain metastasis, triple-negative breast cancer, PPL, MAPK13,265

Breast cancer, apoptosis, GnB1, tumour suppressor gene,PCR, autophagy, 69

Breast cancer, cytology, pleural effusion, dnA methylation,SHOx2, malignant tumour, lung cancer, biomarker,quantitative methylation-specific PCR, 217

Cancer immunotherapy against intracellular targets,autoimmune disease-related antibodies, intracellularimmunization, inhibition of oncogenic pathways,mechanisms of antibody uptake, protein knock-down, targetvalidation, protein transduction domain, review, 239

Cancer, thiamine, vitamin B1, transketolase, tumor, review,169

Capecitabine, DPYD, dPd, 5-FU, pharmacogenetics, 89Caveolin-1, single nucleotide polymorphism, childhood

leukemia, 75Cell invasion, WISP2, colorectal cancer, cell motility, 187Cell motility, WISP2, colorectal cancer, cell invasion, 187Cerebellum, proteome, proteomics, normal mouse brain,

frontal cortex, olfactory bulb, hippocampus, midbrain,hypothalamus, medulla, 125

Childhood leukemia, caveolin-1, single nucleotidepolymorphism, 75

Clear-cell renal cell carcinoma, VeGI, VeGI isoform,angiogenesis, 47

Clinical and pathological data, colorectal cancer, vascularendothelial growth factor, 55

Colon cancer, bioinformatics, diagnosis, gene expression,histopathology, microarrays, QC, RnA, RT-qPCR, staging,statistics, miRnA, stool samples, 93

Colorectal cancer, vascular endothelial growth factor, clinicaland pathological data, 55

Colorectal cancer, WISP2, cell invasion, cell motility, 187Cyclin kinase inhibitors, ovarian cancer, histological subtypes,

prognosis, p21, p21 p53, p21p27, 27Cytokine delivery, antibody formats, death receptors, HeR

signaling, recruitment of immune effector cells, inhibition ofangiogenesis, review, 1

Cytokine receptors, natural killer cells, gene expression,HnSCC, immune surveillance, gene microarrays, 197

Cytology, pleural effusion, dnA methylation, SHOx2,malignant tumour, lung cancer, breast cancer, biomarker,quantitative methylation-specific PCR, 217

death receptors, antibody formats, cytokine delivery, HeRsignaling, recruitment of immune effector cells, inhibition ofangiogenesis, review, 1

diagnosis, bioinformatics, gene expression, histopathology,microarrays, QC, RnA, RT-qPCR, staging, statistics, coloncancer, miRnA, stool samples, 93

dnA methylation, cytology, pleural effusion, SHOx2,malignant tumour, lung cancer, breast cancer, biomarker,quantitative methylation-specific PCR, 217

dPd, DPYD, 5-FU, capecitabine, pharmacogenetics, 89DPYD, dPd, 5-FU, capecitabine, pharmacogenetics, 89

endothelial cell, Rho kinase, ROCK, angiogenesis, tumorvasculature, shRnA, miRnA, microarrays, 251

extension of plasma half-life, angiogenesis, HeR signaling;multivalent, multispecific, pharmacokinetics, phage andribosome display, randomisation of loops and β sheets,review, 155

Frontal cortex, proteome, proteomics, normal mouse brain,olfactory bulb, hippocampus, midbrain, cerebellum,hypothalamus, medulla, 125

5-FU, DPYD, dPd, capecitabine, pharmacogenetics, 89

GADD45A, salivary gland tumours, gene expression, NFkB,JNK1, 81

Gastrointestinal stromal tumors, KIT, PdGFRA, mutationalanalysis, pharmacogenomics, 115

Gene expression, bioinformatics, diagnosis, histopathology,microarrays, QC, RnA, RT-qPCR, staging, statistics, coloncancer, miRnA, stool samples, 93

Gene expression, LnCaP, PnT1A, Selol, oxidative stress, 225Gene expression, natural killer cells, cytokine receptors,

285


HnSCC, immune surveillance, gene microarrays, 197Gene expression, salivary gland tumours, NFkB, GADD45A,

JNK1, 81Gene microarrays, natural killer cells, cytokine receptors, gene

expression, HnSCC, immune surveillance, 197Genomic biomarkers, sporadic colorectal carcinoma,

metastases, proteomic biomarkers, review, 19Genotoxicity test, hydrogen peroxide, micronucleus test, tooth

bleaching, oral mucosa, 209Glycolytic pathway, metabolomics, serum, tissue, amino acid,

head and neck cancer, 233GnB1, breast cancer, apoptosis, tumour suppressor gene, PCR,

autophagy, 69

Head and neck cancer, metabolomics, serum, tissue, glycolyticpathway, amino acid, 233

HeR signaling, antibody formats, cytokine delivery, deathreceptors, recruitment of immune effector cells, inhibition ofangiogenesis, review, 1

HeR signaling; multivalent, angiogenesis, extension of plasmahalf-life, multispecific, pharmacokinetics, phage andribosome display, randomisation of loops and β sheets,review, 155

Hippocampus, proteome, proteomics, normal mouse brain,frontal cortex, olfactory bulb, midbrain, cerebellum,hypothalamus, medulla, 125

Histological subtypes, ovarian cancer, prognosis, cyclin kinaseinhibitors, p21, p21 p53, p21p27, 27

Histopathology, bioinformatics, diagnosis, gene expression,microarrays, QC, RnA, RT-qPCR, staging, statistics, coloncancer, miRnA, stool samples, 93

HnSCC, natural killer cells, cytokine receptors, geneexpression, immune surveillance, gene microarrays, 197

Hydrogen peroxide, genotoxicity test, micronucleus test, toothbleaching, oral mucosa, 209

Hypothalamus, proteome, proteomics, normal mouse brain,frontal cortex, olfactory bulb, hippocampus, midbrain,cerebellum, medulla, 125

Immune surveillance, natural killer cells, cytokine receptors,gene expression, HnSCC, gene microarrays, 197

In silico screening, p53, molecular docking,pharmacogenomics, radioprotection, tumor suppressor,virtual drug screening, 35

Inhibition of angiogenesis, antibody formats, cytokinedelivery, death receptors, HeR signaling, recruitment ofimmune effector cells, review, 1

Inhibition of oncogenic pathways, autoimmune disease-relatedantibodies, cancer immunotherapy against intracellulartargets, intracellular immunization, mechanisms of antibodyuptake, protein knock-down, target validation, proteintransduction domain, review, 239

Intracellular immunization, autoimmune disease-relatedantibodies, cancer immunotherapy against intracellulartargets, inhibition of oncogenic pathways, mechanisms ofantibody uptake, protein knock-down, target validation,protein transduction domain, review, 239

JNK1, salivary gland tumours, gene expression, NFkB,GADD45A, 81

KIT, gastrointestinal stromal tumors, PdGFRA, mutationalanalysis, pharmacogenomics, 115

LnCaP, PnT1A, Selol, gene expression, oxidative stress, 225Lung cancer, cytology, pleural effusion, dnA methylation,

SHOx2, malignant tumour, breast cancer, biomarker,quantitative methylation-specific PCR, 217

Malignant tumour, cytology, pleural effusion, dnAmethylation, SHOx2, lung cancer, breast cancer, biomarker,quantitative methylation-specific PCR, 217

MAPK13, triple-negative breast cancer, brain metastasis, PPL,265

Mechanisms of antibody uptake, autoimmune disease-relatedantibodies, cancer immunotherapy against intracellulartargets, intracellular immunization, inhibition of oncogenicpathways, protein knock-down, target validation, proteintransduction domain, review, 239

Medulla, proteome, proteomics, normal mouse brain, frontalcortex, olfactory bulb, hippocampus, midbrain, cerebellum,hypothalamus, 125

Metabolomics, serum, tissue, glycolytic pathway, amino acid,head and neck cancer, 233

Metastases, sporadic colorectal carcinoma, genomicbiomarkers, proteomic biomarkers, review, 19

Microarrays, bioinformatics, diagnosis, gene expression,histopathology, QC, RnA, RT-qPCR, staging, statistics,colon cancer, miRnA, stool samples, 93

Microarrays, Rho kinase, ROCK, endothelial cell,angiogenesis, tumor vasculature, shRnA, miRnA, 251

Micronucleus test, genotoxicity test, hydrogen peroxide, toothbleaching, oral mucosa, 209

Midbrain, proteome, proteomics, normal mouse brain, frontalcortex, olfactory bulb, hippocampus, cerebellum,hypothalamus, medulla, 125

MiRnA, bioinformatics, diagnosis, gene expression,histopathology, microarrays, QC, RnA, RT-qPCR, staging,statistics, colon cancer, stool samples, 93

MiRnA, Rho kinase, ROCK, endothelial cell, angiogenesis,tumor vasculature, shRnA, microarrays, 251

Molecular docking, p53, pharmacogenomics, radioprotection,tumor suppressor, virtual drug screening, in silico screening,35

Multispecific, angiogenesis, extension of plasma half-life,HeR signaling; multivalent, pharmacokinetics, phage andribosome display, randomisation of loops and β sheets,review, 155

Mutational analysis, gastrointestinal stromal tumors, KIT,PdGFRA, pharmacogenomics, 115

natural killer cells, cytokine receptors, gene expression,HnSCC, immune surveillance, gene microarrays, 197

NFkB, salivary gland tumours, gene expression, GADD45A,JNK1, 81

normal mouse brain, proteome, proteomics, frontal cortex,

286


olfactory bulb, hippocampus, midbrain, cerebellum,hypothalamus, medulla, 125

Olfactory bulb, proteome, proteomics, normal mouse brain,frontal cortex, hippocampus, midbrain, cerebellum,hypothalamus, medulla, 125

Oral mucosa, genotoxicity test, hydrogen peroxide,micronucleus test, tooth bleaching, 209

Ovarian cancer, histological subtypes, prognosis, cyclin kinaseinhibitors, p21, p21 p53, p21p27, 27

Oxidative stress, LnCaP, PnT1A, Selol, gene expression, 225

P21 p53, ovarian cancer, histological subtypes, prognosis,cyclin kinase inhibitors, p21, p21p27, 27

P21, ovarian cancer, histological subtypes, prognosis, cyclinkinase inhibitors, p21 p53, p21p27, 27

P21p27, ovarian cancer, histological subtypes, prognosis,cyclin kinase inhibitors, p21, p21 p53, 27

P53, molecular docking, pharmacogenomics, radioprotection,tumor suppressor, virtual drug screening, in silico screening,35

PCR, breast cancer, apoptosis, GnB1, tumour suppressor gene,autophagy, 69

PdGFRA, gastrointestinal stromal tumors, KIT, mutationalanalysis, pharmacogenomics, 115

Phage and ribosome display, angiogenesis, extension ofplasma half-life, HeR signaling; multivalent, multispecific,pharmacokinetics, randomisation of loops and β sheets,review, 155

Pharmacogenetics, DPYD, dPd, 5-FU, capecitabine, 89Pharmacogenomics, gastrointestinal stromal tumors, KIT,

PdGFRA, mutational analysis, 115Pharmacogenomics, p53, molecular docking, radioprotection,

tumor suppressor, virtual drug screening, in silico screening,35

Pharmacokinetics, angiogenesis, extension of plasma half-life,HeR signaling; multivalent, multispecific, phage andribosome display, randomisation of loops and β sheets,review, 155

Pleural effusion, cytology, dnA methylation, SHOx2,malignant tumour, lung cancer, breast cancer, biomarker,quantitative methylation-specific PCR, 217

PnT1A, LnCaP, Selol, gene expression, oxidative stress, 225PPL, triple-negative breast cancer, brain metastasis, MAPK13,

265Prognosis, ovarian cancer, histological subtypes, cyclin kinase

inhibitors, p21, p21 p53, p21p27, 27Protein knock-down, autoimmune disease-related antibodies,

cancer immunotherapy against intracellular targets,intracellular immunization, inhibition of oncogenicpathways, mechanisms of antibody uptake, target validation,protein transduction domain, review, 239

Protein transduction domain, autoimmune disease-relatedantibodies, cancer immunotherapy against intracellulartargets, intracellular immunization, inhibition of oncogenicpathways, mechanisms of antibody uptake, protein knock-down, target validation, review, 239

Proteome, proteomics, normal mouse brain, frontal cortex,

olfactory bulb, hippocampus, midbrain, cerebellum,hypothalamus, medulla, 125

Proteomic biomarkers, sporadic colorectal carcinoma,metastases, genomic biomarkers, review, 19

Proteomics, proteome, normal mouse brain, frontal cortex,olfactory bulb, hippocampus, midbrain, cerebellum,hypothalamus, medulla, 125

QC, bioinformatics, diagnosis, gene expression,histopathology, microarrays, RnA, RT-qPCR, staging,statistics, colon cancer, miRnA, stool samples, 93

Quantitative methylation-specific PCR, cytology, pleuraleffusion, dnA methylation, SHOx2, malignant tumour,lung cancer, breast cancer, biomarker, 217

Radioprotection, p53, molecular docking, pharmacogenomics,tumor suppressor, virtual drug screening, in silico screening,35

Randomisation of loops and β sheets, angiogenesis, extensionof plasma half-life, HeR signaling; multivalent,multispecific, pharmacokinetics, phage and ribosomedisplay, review, 155

Recruitment of immune effector cells, antibody formats,cytokine delivery, death receptors, HeR signaling, inhibitionof angiogenesis, review, 1

Review, angiogenesis, extension of plasma half-life, HeRsignaling; multivalent, multispecific, pharmacokinetics,phage and ribosome display, randomisation of loops and βsheets, 155

Review, antibody formats, cytokine delivery, death receptors,HeR signaling, recruitment of immune effector cells,inhibition of angiogenesis, 1

Review, autoimmune disease-related antibodies, cancerimmunotherapy against intracellular targets, intracellularimmunization, inhibition of oncogenic pathways,mechanisms of antibody uptake, protein knock-down, targetvalidation, protein transduction domain, 239

Review, sporadic colorectal carcinoma, metastases, genomicbiomarkers, proteomic biomarkers, 19

Review, thiamine, cancer, vitamin B1, transketolase, tumor,169

Rho kinase, ROCK, endothelial cell, angiogenesis, tumorvasculature, shRnA, miRnA, microarrays, 251

RnA, bioinformatics, diagnosis, gene expression,histopathology, microarrays, QC, RT-qPCR, staging,statistics, colon cancer, miRnA, stool samples, 93

ROCK, Rho kinase, endothelial cell, angiogenesis, tumorvasculature, shRnA, miRnA, microarrays, 251

RT-qPCR, bioinformatics, diagnosis, gene expression,histopathology, microarrays, QC, RnA, staging, statistics,colon cancer, miRnA, stool samples, 93

Salivary gland tumours, gene expression, NFkB, GADD45A,JNK1, 81

Selol, LnCaP, PnT1A, gene expression, oxidative stress, 225Serum, metabolomics, tissue, glycolytic pathway, amino acid,

head and neck cancer, 233SHOx2, cytology, pleural effusion, dnA methylation,

287


malignant tumour, lung cancer, breast cancer, biomarker,quantitative methylation-specific PCR, 217

ShRnA, Rho kinase, ROCK, endothelial cell, angiogenesis,tumor vasculature, miRnA, microarrays, 251

Single nucleotide polymorphism, caveolin-1, childhoodleukemia, 75

Sporadic colorectal carcinoma, metastases, genomicbiomarkers, proteomic biomarkers, review, 19

Staging, bioinformatics, diagnosis, gene expression,histopathology, microarrays, QC, RnA, RT-qPCR, statistics,colon cancer, miRnA, stool samples, 93

Statistics, bioinformatics, diagnosis, gene expression,histopathology, microarrays, QC, RnA, RT-qPCR, staging,colon cancer, miRnA, stool samples, 93

Stool samples, bioinformatics, diagnosis, gene expression,histopathology, microarrays, QC, RnA, RT-qPCR, staging,statistics, colon cancer, miRnA, 93

Target validation, autoimmune disease-related antibodies,cancer immunotherapy against intracellular targets,intracellular immunization, inhibition of oncogenicpathways, mechanisms of antibody uptake, protein knock-down, protein transduction domain, review, 239

Thiamine, cancer, vitamin B1, transketolase, tumor, review,169

Tissue, metabolomics, serum, glycolytic pathway, amino acid,head and neck cancer, 233

Tooth bleaching, genotoxicity test, hydrogen peroxide,micronucleus test, oral mucosa, 209

Transketolase, thiamine, cancer, vitamin B1, tumor, review,169

Triple-negative breast cancer, brain metastasis, PPL, MAPK13,265

Tumor suppressor, p53, molecular docking,pharmacogenomics, radioprotection, virtual drug screening,in silico screening, 35

Tumor vasculature, Rho kinase, ROCK, endothelial cell,angiogenesis, shRnA, miRnA, microarrays, 251

Tumor, thiamine, cancer, vitamin B1, transketolase, review,169

Tumour suppressor gene, breast cancer, apoptosis, GnB1,PCR, autophagy, 69

Vascular endothelial growth factor, colorectal cancer, clinicaland pathological data, 55

VeGI isoform, VeGI, clear-cell renal cell carcinoma,angiogenesis, 47

VeGI, VeGI isoform, clear-cell renal cell carcinoma,angiogenesis, 47

Virtual drug screening, p53, molecular docking,pharmacogenomics, radioprotection, tumor suppressor, insilico screening, 35

Vitamin B1, thiamine, cancer, transketolase, tumor, review,169

WISP2, colorectal cancer, cell invasion, cell motility, 187


288


289

Ahmed Fe, 93Ahmed nC, 93Alcazar Montero JA, 19Allison RR, 93Anagnostopoulos AK, 125Anuszewska e, 225Atkins Jn, 93Auer J, 155Bau d-T, 75Bauer M, 81Bengoechea O, 19Biesterfeld S, 217Blanco Muñez O, 19Bonnerup C, 93Böttcher A, 197Brinkmann U, 1, 155, 239Bryan BA, 251Casey M, 93Chang W-S, 75Chiu C-F, 75Cho S-G, 265Choi Y-K, 265Conti S, 115Costarelli L, 115Covello R, 115de Marchis ML, 115della-Morte d, 115dommerich S, 197efferth T, 35eichhorn T, 35ember I, 81Ferroni P, 115Filho AL, 55Fink C, 217Frank M, 35Frewer KA, 187Frewer nC, 187Fuentes M, 19

Fujita T, 233Garcia eA, 55Garcia Garcia J, 19Georges G, 1, 155Gerlinger I, 81Gőbel G, 81Gocze K, 81Gombos K, 81Gong K, 47González Fernandez LM, 19González-González M, 19Guadagni F, 115Hargest R, 187Hiller C, 35Hirschfelder K, 35Ilse P, 217Irino Y, 233Jang BH, 265Jiang WG, 47, 69, 187Kasuba V, 209Kim J-H, 265Kim JW, 265Kitamotomatsuda J, 233Klaric e, 209Knecht R, 197Ko S-G, 265Koczan d, 197Kopjar n, 209Kouskoukis A, 125Kramp B, 197Krauth-Siegel RL, 35Ksiazek I, 225Kurisetty V, 251Lai Y-L, 75Lane H-Y, 75Leone B, 115Lin C-C, 75Ludovici G, 115

Lương KVQ, 169Luz MAM, 55Maisel d, 239Margaritis LH, 125Martins SF, 55Mertens R, 35Mitchell dC, 251Mokbel K, 69Moon He, 265Morimoto K, 233Mota H, 93Müller R, 35naziri W, 93németh Α, 81nguyễn LTH, 169nibu K-I, 233nishiumii S, 233noh d-Y, 265nuovo GJ, 93Orfao A, 19Ostwald J, 197Otsuki n, 233Owen S, 187Paek SH, 265Palmirotta R, 115Par M, 209Pardal F, 55Pomjanski n, 217Profeta I, 209Révész P, 81Rodrigues M, 55Roselli M, 115Roslon M, 225Rozgaj R, 209Saif MW, 89Saito M, 233Sanders AJ, 187Sayagues JM, 19

Schramm M, 217Seidal T, 27Shan H, 47Sharma AK, 69Shayiremu d, 47Shin Hd, 265Shin YC, 265Shinohara M, 233Sitarz K, 225Skirnisdottir I, 27Stiles JM, 251Stravopodis dJ, 125Suchocki P, 225Szanyi I, 81Taraslia VK, 125Tarle Z, 209Tiefenthaler G, 1, 155, 239Tsai F-J, 75Tsangaris GTH, 125Vos PW, 93Wang C-H, 75Wazir U, 69Weidle UH, 1, 155, 239Weiss eH, 1Wilczynska Jd, 225Wiley Je, 93Woo S-M, 265Wu K-H, 75Wu L, 47Wu P, 47Yamashita d, 233Yang Y, 47Ye L, 47Yonezawa K, 233Yoshida M, 233Yun YJ, 265Zeljezic d, 209Zhang n, 477

Authors Index(Figures refer to page numbers)

CAnCeR GenOMICS & PROTeOMICS supports (a)the aims and the research projects of theInTeRnATIOnAL InSTITUTe OF AnTICAnCeRReSeARCH (IIAR, Kapandriti, Attiki, Greece) and (b)the organization of the International Conferences ofAnticancer Research.CAnCeR GenOMICS & PROTeOMICS appearsonline with Stanford University HighWire Press.For more information about CAnCeR GenOMICS &PROTeOMICS, IIAR and the Conferences please visit ourwebsites: www.iiar-anticancer.org, www.cgp.iiarjournals.orgPublication Data: CAnCeR GenOMICS &PROTeOMICS (CGP) is published bimonthly. eachannual volume contains six issues. Annual Authors andSubject Indexes are included in the sixth issue of eachvolume.Copyright: Once a manuscript has been published inCGP, which is a copyrighted publication, the legalownership of all published parts of the paper passes fromthe Author to the Journal.

Manuscripts, correspondence, requests for sample copiesand orders should be addressed to: dr. John G.delinasios, Managing editor, editorial Office, CancerGenomics & Proteomics, 1st km Kapandritiou-KalamouRoad, P.O. Box 22, Kapandriti, Attiki, 19014, Greece.Tel: +30 22950 52945, Fax: +30 22950 53389, e-mail:[email protected] (editorial Office),[email protected] (Managing editor).Manuscripts from north America may be sent to theeditor-in-Chief, Prof. A. Seth, CGP, Laboratory ofMolecular Pathology, Sunnybrook Research Institute,Sunnybrook Health Sicences Centre, 2075 BayviewAvenue, Toronto, On, Canada M4n 3M5. Fax: 416 9785956, e-mail: genomics. [email protected] Subscription. CAnCeR GenOMICS &PROTeOMICS is converted to an online-only openaccess journal from January 2013 (Volume 10)The editors and Publishers of the journal CAnCeRGenOMICS & PROTeOMICS accept no responsibilityfor the opinions expressed by the contributors or for thecontent of the advertisements appearing therein.

Documents

CAnCeR GenOMICS & PROTeOMICS - …cgp.iiarjournals.org/content/10/6/277.full.pdf · Articles in CAnCeR GenOMICS & PROTeOMICS are regularly indexed in the ... Y. YAnG (Beijing; Hami,